Stefanie Marti

Stefanie Marti

Auto-generated profile, based on publicly available information

Stefanie Marti

Department of Neurology, Inselspital, Bern University Hospital and University of Bern , 3010 Bern

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2016 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
RPRiccardo Delli Ponti
Riccardo Delli Ponti
SMStefanie Marti
Stefanie Marti
AAAlexandros Armaos
Alexandros Armaos
Gian Gaetano TartagliaGian Gaetano Tartaglia
Gian Gaetano Tartaglia
Here we introduce the Computational Recognition of Secondary Structure (CROSS) method to calculate the structural profile of an RNA sequence (single- or double-stranded state) at single-nucleotide resolution and without sequence length restrictions. We trained CROSS using data from high-throughput experiments such as Selective 2΄-Hydroxyl Acylation analyzed by Primer Extension (SHAPE; Mouse and HIV transcriptomes) and Parallel Analysis of RNA Structure (PARS; Human and Yeast transcriptomes) as well as high-quality NMR/X-ray structures (PDB database). The algorithm uses primary structure information alone to predict experimental structural profiles with >80% accuracy, showing high performances on large RNAs such as Xist (17 900 nucleotides; Area Under the ROC Curve AUC of 0.75 on dimethyl sulfate (DMS) experiments). We integrated CROSS in thermodynamics-based methods to predict secondary structure and observed an increase in their predictive power by up to 30%.

3 February 2014 in Journal of High Energy Physics
Verified
Journal Article
Open access
PDF file
TBThomas Becher
Thomas Becher
GBGuido Bell
Guido Bell
CLChristian Lorentzen
Christian Lorentzen
SMStefanie Marti
Stefanie Marti
We obtain the next-to-next-to-leading order corrections to transverse-momentum spectra of W, Z and Higgs bosons near the partonic threshold. In the threshold limit, the electroweak boson recoils against a low-mass jet and all radiation is either soft, or collinear to the jet or the beam directions. We extract the virtual corrections from known results for the relevant two-loop four-point amplitudes and combine them with the soft and collinear two-loop functions as defined in Soft-Collinear Effective Theory. We have implemented these results in a public code PeTeR and present numerical results for the threshold resummed cross section of W and Z bosons at next-to-next-to-next-to-leading logarithmic accuracy, matched to next-to-leading fixed-order perturbation theory. The two-loop corrections lead to a moderate increase in the cross section and reduce the scale uncertainty by about a factor of two. The corrections are significantly larger for Higgs production.

3 July 2017 in Brain
Verified
Journal Article
Open access
PDF file
EGEllen Gelpi
Ellen Gelpi
TBTeresa Botta-Orfila
Teresa Botta-Orfila
LBLaia Bodi
Laia Bodi
SMStefanie Marti
Stefanie Marti
Gabor G. KovacsGabor G. Kovacs
Gabor G. Kovacs
MMMontserrat Milà
Montserrat Milà

6 April 2012 in Journal of High Energy Physics
Verified
Journal Article
Closed access
PDF file
TBThomas Becher
Thomas Becher
GBGuido Bell
Guido Bell
SMStefanie Marti
Stefanie Marti

6 November 2014 in Journal of High Energy Physics
Verified
Journal Article
Open access
PDF file
TBThomas Becher
Thomas Becher
GBGuido Bell
Guido Bell
CLChristian Lorentzen
Christian Lorentzen
SMStefanie Marti
Stefanie Marti
We give next-to-next-to-leading order (NNLO) predictions for the Higgs production cross section at large transverse momentum in the threshold limit. Near the partonic threshold, all radiation is either soft or collinear to the final state jet which recoils against the Higgs boson. We find that the real emission corrections are of moderate size, but that the virtual corrections are large. We discuss the origin of these corrections and give numerical predictions for the transverse-momentum spectrum. The threshold result is matched to the known NLO result and implemented in the public code PeTeR.Comment: 17 pages, 9 Figures; v2: journal version, correction in the qg channe

7 April 2025 in BMC Medicine
Verified
Journal Article
Open access
PDF file
MMMarine Massy
Marine Massy
SMStefanie Marti
Stefanie Marti
HHHelly Hammer
Helly Hammer
RHRobert Hoepner
Robert Hoepner
Semaglutide, a GLP-1 receptor agonist widely prescribed for type 2 diabetes and obesity, has recently raised concerns about its ocular safety. This study aimed to investigate the association between semaglutide use and vision impairment using data from the FDA Adverse Event Reporting System (FAERS). We conducted an analysis of FAERS data, comparing reports of vision impairment associated with semaglutide to those associated with other antidiabetic and weight loss medications. The main outcome measure was the reporting odds ratio (rOR) for vision impairment linked to semaglutide use compared to other medications. Semaglutide showed significantly higher reporting of vision impairment compared to other GLP-1 receptor agonists (rOR 1.95, 95% CI 1.75–2.17, p < 0.0001), DPP-4 inhibitors (rOR 2.46, 95% CI 2.12–2.86, p < 0.0001), SGLT2 inhibitors (rOR 3.89, 95% CI 3.35–4.51, p < 0.0001), and metformin (rOR 2.23, 95% CI 1.90–2.62, p < 0.0001). Similar findings were observed when compared to phentermine (rOR 1.57, 95% CI 1.07–2.31, p = 0.026) and orlistat (rOR 3.77, 95% CI 2.96–4.81, p < 0.0001). Topiramate was the sole exception, showing higher vision impairment reporting than semaglutide (rOR 0.30, 95% CI 0.20–0.45, p < 0.0001). These findings suggest a potentially elevated risk of vision impairment with semaglutide use compared to other diabetes and weight loss medications, warranting further investigation and vigilant post-marketing surveillance. Future studies should assess the clinical impact of this potential increased risk on an absolute scale to better inform treatment decisions.